SciSparc Announces MitoCareX Confirms Potential Significant Role Of Its Drug Target In NSCLC
Portfolio Pulse from Benzinga Newsdesk
SciSparc Ltd. (NASDAQ: SPRC) announced that its venture, MitoCareX Bio Ltd., has confirmed the significant role of its drug target in Non-Small Cell Lung Cancer (NSCLC) using advanced genetic and 3D spheroid systems. This discovery could impact the NSCLC market, projected to reach $59.77 billion by 2030.
July 22, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SciSparc Ltd. (SPRC) announced a significant discovery in NSCLC treatment through its venture MitoCareX Bio Ltd. This could enhance the company's position in the lucrative NSCLC market, projected to reach $59.77 billion by 2030.
The confirmation of the significant role of SciSparc's drug target in NSCLC could lead to increased investor confidence and potential partnerships, driving the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100